Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Sponsor
Vienna Institute for Research in Ocular Surgery
Study ID
NCT07390253
Status
Active Not Recruiting

Conditions

  • Neovascular (Wet) Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
21 Years - 105 Years
Healthy Volunteers
Not accepted

Interventions

  • Aflibercept — DRUG
    Intravitreal injection with high dose (8 mg) aflibercept

Study Details

This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.

Key Dates

Start date
Sep 18, 2024
Status verified
Feb 2026
Primary completion
Feb 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: neovascular age-related macular degeneration (nAMD)
    Patient suffering from neovascular age-related macular degeneration (nAMD)

Primary Outcome Measure

Number of intravitreal injections [ Time Frame: 12 months ]

Related Studies